[Abstract Only] Randomized Trial: Treatments for Patients with Multiple Myeloma Eligible for Transplantation Compared
30 Jun, 2019 | 17:20h | UTCBortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)
Commentary: EHA 2019: CASSIOPEIA Trial Examines Addition of Daratumumab to Standard Treatment Before and After ASCT in Multiple Myeloma – The ASCO Post (free)